摘要
目的分析腹腔热灌注化疗(intraperitoneal hyperthermia chemotherapy,IHPC)与顺铂+紫杉醇化疗(cisplatin plus paclitaxel,TP)在晚期卵巢癌临床治疗中的应用效果。方法以我院于2018年12月—2019年10月收治的70例晚期卵巢癌患者展开研究,根据随机双盲法分成对照组(TP化疗)与试验组(IHPC+TP化疗),每组各35例;比对两组患者的治疗总有效率以及治疗后的肿瘤标志物水平、卡氏评分(Karnofsky,KPS)。结果试验组治疗总有效率为60.00%,与对照组的31.43%比较,差异统计学意义明显(P<0.05);试验组治疗后血清CEA与CA125水平低于对照组,KPS评分高于对照组,差异统计学意义明显(P<0.05)。结论晚期卵巢癌患者行IHPC+TP疗法,可改善病情,有利于患者预后。
Objective To analyze the effect of intraperitoneal hyperthermia chemotherapy(IHPC)and cisplatin+paclitaxel chemotherapy(Ppaclitaxel plus cisplatin(TP))in the clinical treatment of advanced ovarian cancer.Methods A study was performed on 70 patients with advanced ovarian cancer treated in our hospital from December 2018 to October 2019.According to the random double-blind method,they were divided into control group(TP chemotherapy)and test group(IHPC+TP chemotherapy),with 35 cases in each group.The total effective rate of treatment and the tumor marker levels and KPS after treatment were compared between the two groups.Results The total effective rate of treatment in the test group was 60.00%,compared with 31.43%in the control group,and the difference was statistically significant(P<0.05).Serum CEA and CA125 levels in the test group were lower than those in the control group,and KPS scores were higher than in the control group.The difference was statistically significant(P<0.05).Conclusion IHPC+TP therapy for patients with advanced ovarian cancer can improve the condition and be beneficial to the prognosis of patients.
作者
刘成成
LIU Chengcheng(Department of Gynecology,Yankuang New Mile General Hospital,Zoucheng Shandong 273500,China)
出处
《中国卫生标准管理》
2020年第16期51-53,共3页
China Health Standard Management
